Incidence of Kidney Disease

FierceBiotech  Jul 13  Comment 
Allena Pharma has been granted orphan status by the FDA for a drug to treat primary hyperoxaluria, a rare disease that causes kidney and bladder stones and can lead to kidney failure and death.
MarketWatch  Jul 12  Comment 
Shares of Cara Therapeutics Inc. surged 13.7% in premarket trade Wednesday, after the company reported positive results in an early-stage trial of a treatment for chronic kidney disease-associated pruritus patients, or CKD-aP. Pruritus, or itch,...
MedPage Today  Jul 7  Comment 
(MedPage Today) -- No contrast volume reduction for patients at risk for kidney failure
The Economic Times  Jul 5  Comment 
Anaemia commonly arises in kidney disease patients, because the kidneys no longer produce sufficient amounts of erythropoietin, a hormone which stimulates red blood cell production.
Motley Fool  Jun 30  Comment 
Investor optimism for its new pain drug has sent shares soaring recently, but poor performance of an oral formulation in trials dampens spirits.
Motley Fool  Jun 26  Comment 
Investor optimism remains high, following news that Cara's lead drug candidate received FDA breakthrough-therapy status for use in patients with kidney disease.
Benzinga  Jun 23  Comment 
Cara Therapeutics Inc (NASDAQ: CARA) shares are trading higher by $2.50 (12 percent) at $22.38 in Friday's session. The catalyst for the rally is the announcement that the IV CR845 has received Breakthrough Therapy designation for the treatment...
The Hindu Business Line  Jun 15  Comment 
Shares of Aurobindo Pharma today surged almost 7 per cent as the company received USFDA nod to make oral suspension used for controlling serum phosphorus in patients with chronic kidney disease on di...
The Economic Times  Jun 15  Comment 
Sevelamer Carbonate oral suspension is indicated for the control of serum phosphorus in patients with chronic kidney disease (CKD) on dialysis.

Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki